Upgrade to SI Premium - Free Trial

Fortress Biotech (FBIO)

2.85 +0.20 (7.55%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/12/26 *Est.)

Latest Headlines

Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference May 19, 2026 4:45 PM - StreetInsider Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference May 18, 2026 8:30 AM - Globe NewsWire Form SCHEDULE 13G/A Fortress Biotech, Inc. Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC May 15, 2026 6:35 AM - SEC Filing Form 10-Q Fortress Biotech, Inc. For: Mar 31 May 14, 2026 4:32 PM - SEC Filing Form 8-K Fortress Biotech, Inc. For: May 14 May 14, 2026 4:23 PM - SEC Filing Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights May 14, 2026 4:10 PM - StreetInsider Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights May 13, 2026 4:01 PM - StreetInsider Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 May 6, 2026 4:01 PM - StreetInsider Form 10-Q MUSTANG BIO, INC. For: Mar 31 May 5, 2026 4:02 PM - SEC Filing Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference May 4, 2026 8:30 AM - Globe NewsWire Form DEFA14A Fortress Biotech, Inc. April 28, 2026 4:20 PM - SEC Filing Form DEF 14A Fortress Biotech, Inc. For: Jun 17 April 28, 2026 4:16 PM - SEC Filing Form 4 MUSTANG BIO, INC. For: Apr 24 Filed by: Litchman Manuel MD April 27, 2026 4:06 PM - SEC Filing Journey Medical secures third major GPO contract for Emrosi rosacea drug April 21, 2026 8:30 AM - StreetInsider Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™ April 21, 2026 8:30 AM - StreetInsider Form 8-K MUSTANG BIO, INC. For: Apr 15 April 17, 2026 4:02 PM - SEC Filing Form 4 Fortress Biotech, Inc. For: Apr 01 Filed by: Jin David April 1, 2026 4:05 PM - SEC Filing Form 10-K Fortress Biotech, Inc. For: Dec 31 March 31, 2026 5:06 PM - SEC Filing Form 8-K Fortress Biotech, Inc. For: Mar 31 March 31, 2026 4:16 PM - SEC Filing Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights March 31, 2026 4:05 PM - StreetInsider Form 8-K Fortress Biotech, Inc. For: Mar 30 March 30, 2026 5:34 PM - SEC Filing Cyprium Therapeutics sells rare disease priority review voucher for $205 million March 30, 2026 4:05 PM - StreetInsider Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million March 30, 2026 4:05 PM - StreetInsider Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights March 25, 2026 4:01 PM - StreetInsider Form SCHEDULE 13D/A Fortress Biotech, Inc. Filed by: ROSENWALD LINDSAY A MD March 20, 2026 4:16 PM - SEC Filing Form 4 Fortress Biotech, Inc. For: Mar 18 Filed by: ROSENWALD LINDSAY A MD March 20, 2026 4:05 PM - SEC Filing Form 4 Fortress Biotech, Inc. For: Mar 18 Filed by: WEISS MICHAEL S March 20, 2026 4:05 PM - SEC Filing Form 10-K MUSTANG BIO, INC. For: Dec 31 March 19, 2026 4:06 PM - SEC Filing Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 March 18, 2026 8:30 AM - StreetInsider Full Article List